Certara (CERT) Projected to Post Quarterly Earnings on Thursday

Certara (NASDAQ:CERT) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $0.0866 per share and revenue of $92.01 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The company had revenue of $93.27 million for the quarter, compared to analysts’ expectations of $98.09 million. During the same period last year, the business earned $0.07 EPS. The company’s quarterly revenue was down 10.8% compared to the same quarter last year. On average, analysts expect Certara to post $0.21 EPS for the current fiscal year and $0.28 EPS for the next fiscal year.

Certara Price Performance

Shares of CERT opened at $10.69 on Tuesday. Certara has a 1-year low of $4.45 and a 1-year high of $11.88. The stock has a market cap of $1.63 billion, a PE ratio of -23.74 and a beta of 1.42. The firm has a 50-day simple moving average of $9.06 and a two-hundred day simple moving average of $7.31. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CERT. UBS Group lowered shares of Certara from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a report on Wednesday, September 30th. TD Cowen lifted their target price on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. KeyCorp boosted their target price on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Weiss Ratings cut Certara from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. Finally, Barclays upped their price target on Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $9.18.

About Certara

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.